EA201301108A1 - Биспецифические связывающие молекулы, связывающиеся с vegf и ang2 - Google Patents

Биспецифические связывающие молекулы, связывающиеся с vegf и ang2

Info

Publication number
EA201301108A1
EA201301108A1 EA201301108A EA201301108A EA201301108A1 EA 201301108 A1 EA201301108 A1 EA 201301108A1 EA 201301108 A EA201301108 A EA 201301108A EA 201301108 A EA201301108 A EA 201301108A EA 201301108 A1 EA201301108 A1 EA 201301108A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ang2
vegf
binding molecules
bispecific binding
molecules connecting
Prior art date
Application number
EA201301108A
Other languages
English (en)
Other versions
EA025148B1 (ru
Inventor
Андреас Гшвинд
Рене Георг Отт
Жоашен Букно
Мари-Анж Бюйз
Эрик Депла
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301108(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201301108A1 publication Critical patent/EA201301108A1/ru
Publication of EA025148B1 publication Critical patent/EA025148B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В заявке описаны биспецифические связывающие молекулы, которые связываются и с VEGF, и с Ang2, предпочтительно в форме иммуноглобулиновых единичных вариабельных доменов типа VHH и доменных антител, фармацевтические композиции, содержащие их, и их применение для лечения заболеваний, которые ассоциированы с опосредуемыми VEGF и/или опосредуемыми Ang2 воздействиями на ангиогенез. Кроме того, описаны нуклеиновые кислоты, кодирующие биспецифические связывающие молекулы, клетки-хозяева и способы их получения.
EA201301108A 2011-04-01 2012-03-30 БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2 EA025148B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01
PCT/EP2012/055901 WO2012131078A1 (en) 2011-04-01 2012-03-30 Bispecific binding molecules binding to vegf and ang2

Publications (2)

Publication Number Publication Date
EA201301108A1 true EA201301108A1 (ru) 2014-03-31
EA025148B1 EA025148B1 (ru) 2016-11-30

Family

ID=45895502

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201301108A EA025148B1 (ru) 2011-04-01 2012-03-30 БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С VEGF И Ang2
EA201600338A EA036746B1 (ru) 2011-04-01 2012-03-30 Биспецифическая связывающая молекула, связывающаяся с vegf и ang2

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201600338A EA036746B1 (ru) 2011-04-01 2012-03-30 Биспецифическая связывающая молекула, связывающаяся с vegf и ang2

Country Status (35)

Country Link
US (4) US9527925B2 (ru)
EP (2) EP3144322A3 (ru)
JP (2) JP6023786B2 (ru)
KR (1) KR101907572B1 (ru)
CN (2) CN103562222B (ru)
AP (1) AP2013007085A0 (ru)
AR (1) AR085984A1 (ru)
AU (2) AU2012237234B2 (ru)
BR (1) BR112013025304B1 (ru)
CA (1) CA2827817C (ru)
CL (1) CL2013002623A1 (ru)
CO (1) CO6801639A2 (ru)
CY (1) CY1118339T1 (ru)
DK (1) DK2694546T3 (ru)
EA (2) EA025148B1 (ru)
EC (1) ECSP13013001A (ru)
ES (1) ES2606302T3 (ru)
HK (2) HK1225400A1 (ru)
HR (1) HRP20161689T1 (ru)
HU (1) HUE030148T2 (ru)
IL (1) IL227936B (ru)
LT (1) LT2694546T (ru)
MA (1) MA34979B1 (ru)
MX (2) MX343440B (ru)
MY (1) MY171007A (ru)
PE (1) PE20140448A1 (ru)
PL (1) PL2694546T3 (ru)
PT (1) PT2694546T (ru)
RS (1) RS55361B1 (ru)
SG (2) SG193561A1 (ru)
SI (1) SI2694546T1 (ru)
TN (1) TN2013000390A1 (ru)
UA (1) UA114707C2 (ru)
UY (1) UY33998A (ru)
WO (1) WO2012131078A1 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
IN2014DN06904A (ru) * 2012-03-30 2015-05-15 Boehringer Ingelheim Int
AU2013288641B2 (en) 2012-07-13 2017-07-06 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
MX2015003895A (es) * 2012-09-28 2015-07-17 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2/dll4 y agentes anti-vegf-r.
EA201500371A1 (ru) * 2012-09-28 2015-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
AR103477A1 (es) 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
EP3277713A1 (en) * 2015-03-31 2018-02-07 VHsquared Limited Polypeptides
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
ES2828694T3 (es) * 2015-07-29 2021-05-27 Allergan Inc Anticuerpos sólo de cadena pesada frente a ANG-2
US10308711B2 (en) 2015-08-14 2019-06-04 Allergan, Inc. Heavy chain only antibodies to PDGF
BR112018005737A2 (pt) * 2015-09-23 2018-10-09 Genentech Inc anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
CN115925919A (zh) * 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
PE20181515A1 (es) 2015-12-04 2018-09-21 Boehringer Ingelheim Int Polipeptidos biparatopicos que antagonizan la senalizacion wnt en celulas tumorales
EP3783022A3 (en) 2016-08-23 2021-06-30 MedImmune Limited Anti-vegf-a antibodies and uses thereof
IL264962B1 (en) * 2016-08-23 2024-05-01 Medimmune Ltd Antibodies against VEGF-A and against ANG2 and their uses
US11033490B2 (en) * 2016-12-14 2021-06-15 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
MY200744A (en) 2017-05-31 2024-01-13 Boehringer Ingelheim Int Polypeptides antagonizing wnt signaling in tumor cells
CA3061053A1 (en) 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Anti-cancer combination therapy
CN111699004A (zh) 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
WO2019246273A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
EP3813864A4 (en) 2018-06-29 2022-07-20 Gensun Biopharma Inc. ANTITUMOR ANTAGONISTS
PE20211865A1 (es) 2018-10-29 2021-09-21 Hoffmann La Roche Formulacion de anticuerpos
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
CN114340735A (zh) 2019-06-28 2022-04-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
CN115916816A (zh) * 2019-12-11 2023-04-04 库利南肿瘤股份有限公司 抗血清白蛋白抗体
WO2021155151A1 (en) * 2020-01-29 2021-08-05 The Methodist Hospital System Multivalent ligands targeting cell surface receptors and force measurement platform for making the same
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
WO2022010273A1 (ko) 2020-07-07 2022-01-13 주식회사 카나프테라퓨틱스 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도
JP2023550591A (ja) 2020-11-02 2023-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
EP4019548A1 (en) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Anti lag3 vhhs and their use
US20220389120A1 (en) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Multispecific antagonists
CA3221192A1 (en) * 2021-06-04 2022-12-08 Innovent Biologics (Suzhou) Co. Ltd. Bispecific binding molecule binding to vegf and ang2 and use thereof
AU2022327397A1 (en) * 2021-08-13 2024-03-14 Innovent Biologics (Suzhou) Co., Ltd. Anti-vegf a and -vegf c bispecific antibody and use thereof
KR20240048555A (ko) * 2021-09-10 2024-04-15 소테르 바이오파마 피티이. 리미티드 항 ang2 항체 및 그 제조방법과 응용
CU20210101A7 (es) * 2021-12-15 2023-07-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen a factores de crecimiento proangiogénicos
WO2024055996A1 (zh) * 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 一种抗vegfa抗体或其抗原结合片段及其应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
JP2005518805A (ja) 2002-03-01 2005-06-30 ボール・ホーティカルチャラル・カンパニー 花組織においてトランスジーンを発現させるためのｌｉｓプロモーター
WO2004024764A1 (en) 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
EP3299393A1 (en) * 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
AU2003300133B2 (en) 2002-12-31 2008-11-13 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
ATE414106T1 (de) 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
KR101501870B1 (ko) 2003-08-27 2015-03-12 옵쏘테크 코포레이션 안구의 혈관신생성 장애를 치료하기 위한 조합 치료법
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
NZ555286A (en) 2004-12-17 2010-04-30 Genentech Inc Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
RU2394839C2 (ru) 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
PL1888641T3 (pl) * 2005-05-18 2012-05-31 Ablynx Nv Białka wiążące albuminę surowicy
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
US8377398B2 (en) 2005-05-31 2013-02-19 The Board Of Regents Of The University Of Texas System Methods and compositions related to determination and use of white blood cell counts
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2621226A1 (en) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methods for using and identifying modulators of delta-like 4
CN101305426A (zh) 2005-09-30 2008-11-12 富士通株式会社 信息存储装置
CN101370519B (zh) 2005-12-15 2013-07-24 阿斯利康(瑞典)有限公司 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
WO2007070671A2 (en) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
WO2007085815A2 (en) 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
EP2032604A2 (en) 2006-06-06 2009-03-11 Genentech, Inc. Anti-dll4 antibodies and methods using same
NZ574794A (en) 2006-08-07 2011-06-30 Regeneron Pharma Use of delta-like ligand 4 (DLL4) antagonists for treating eye vascular and ischemic injury
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101528767A (zh) 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
MX2009004027A (es) 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
NZ614857A (en) 2007-03-29 2015-04-24 Genmab As Bispecific antibodies and methods for production thereof
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
MX2009013137A (es) 2007-06-06 2010-04-30 Domantis Ltd Metodos para seleccionar polipeptidos resistentes a la proteasa.
CN101679511A (zh) 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
EP2212432A4 (en) 2007-10-22 2011-10-19 Schering Corp COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES
US9023351B2 (en) 2007-11-26 2015-05-05 Bayer Intellectual Property Gmbh Anti-mesothelin antibodies and uses thereof
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CA3146422A1 (en) 2008-03-18 2009-09-24 Genentech, Inc. Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
US8349322B2 (en) 2008-06-25 2013-01-08 ESBATech, an Alcon Biomedical Research Unit, LLC Stable and soluble antibodies inhibiting VEGF
AU2009288167B2 (en) 2008-09-03 2015-10-22 Genentech, Inc. Multispecific antibodies
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2364328A2 (en) 2008-12-10 2011-09-14 Ablynx NV Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US9805165B2 (en) 2009-01-13 2017-10-31 Fio Corporation Handheld diagnostic test device and method for use with an electronic device and a test cartridge in a rapid diagnostic test
WO2010124009A2 (en) 2009-04-21 2010-10-28 Schering Corporation Fully human anti-vegf antibodies and methods of using
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2443150B1 (en) 2009-06-17 2015-01-21 AbbVie Biotherapeutics Inc. Anti-vegf antibodies and their uses
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
KR20190143480A (ko) 2010-02-23 2019-12-30 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012012499A1 (en) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Optical reader system
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
KR20130118892A (ko) 2010-11-02 2013-10-30 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
KR20140043351A (ko) 2011-05-27 2014-04-09 노파르티스 아게 시력 장애의 치료 방법
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
IN2014DN06904A (ru) * 2012-03-30 2015-05-15 Boehringer Ingelheim Int
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Also Published As

Publication number Publication date
IL227936B (en) 2018-06-28
CY1118339T1 (el) 2017-06-28
AU2012237234A1 (en) 2013-09-05
AR085984A1 (es) 2013-11-13
PT2694546T (pt) 2016-12-28
CN105820243A (zh) 2016-08-03
NZ614249A (en) 2015-05-29
US20220017642A1 (en) 2022-01-20
BR112013025304B1 (pt) 2022-10-11
AU2017200237B2 (en) 2018-05-17
CL2013002623A1 (es) 2014-02-14
EA036746B1 (ru) 2020-12-16
IL227936A0 (en) 2013-09-30
KR20140018317A (ko) 2014-02-12
EP2694546B1 (en) 2016-09-21
AU2017200237A1 (en) 2017-02-02
HK1225400A1 (zh) 2017-09-08
EA201600338A1 (ru) 2016-09-30
RS55361B1 (sr) 2017-03-31
JP6297657B2 (ja) 2018-03-20
MX337543B (es) 2016-03-10
EA025148B1 (ru) 2016-11-30
US20200010569A1 (en) 2020-01-09
US10414828B2 (en) 2019-09-17
ECSP13013001A (es) 2013-12-31
SI2694546T1 (sl) 2017-01-31
US20130078248A1 (en) 2013-03-28
TN2013000390A1 (en) 2015-01-20
UY33998A (es) 2012-09-28
JP2014515602A (ja) 2014-07-03
CO6801639A2 (es) 2013-11-29
JP6023786B2 (ja) 2016-11-09
SG10201602373TA (en) 2016-05-30
SG193561A1 (en) 2013-11-29
EP3144322A2 (en) 2017-03-22
US20170247475A1 (en) 2017-08-31
US11161916B2 (en) 2021-11-02
WO2012131078A1 (en) 2012-10-04
CN103562222A (zh) 2014-02-05
BR112013025304A2 (pt) 2017-06-06
US9527925B2 (en) 2016-12-27
HRP20161689T1 (hr) 2017-02-24
HUE030148T2 (en) 2017-04-28
AP2013007085A0 (en) 2013-08-31
CN103562222B (zh) 2016-04-06
HK1190412A1 (zh) 2014-07-04
DK2694546T3 (en) 2016-12-05
CA2827817A1 (en) 2012-10-04
ES2606302T3 (es) 2017-03-23
EP2694546A1 (en) 2014-02-12
AU2012237234B2 (en) 2016-10-20
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
KR101907572B1 (ko) 2018-10-15
MA34979B1 (fr) 2014-03-01
JP2017023152A (ja) 2017-02-02
LT2694546T (lt) 2016-11-10
MX343440B (es) 2016-11-07
EP3144322A3 (en) 2017-05-31
CA2827817C (en) 2020-12-15
PE20140448A1 (es) 2014-04-13
MY171007A (en) 2019-09-23
UA114707C2 (uk) 2017-07-25

Similar Documents

Publication Publication Date Title
EA201301108A1 (ru) Биспецифические связывающие молекулы, связывающиеся с vegf и ang2
EA201200549A1 (ru) Dll4-связывающие молекулы
CY1122007T1 (el) Μορια δεσμευσης-ang2
EA201301109A1 (ru) БИСПЕЦИФИЧЕСКИЕ СВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Dll4 И Ang2
EA201300311A1 (ru) Vegf-связывающие молекулы
EA201200548A1 (ru) Биспецифические связывающие молекулы для антиангиогенезной терапии
PH12014502527B1 (en) St2 antigen binding proteins
WO2014004549A3 (en) Anti-mesothelin binding proteins

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM